Switzerland’s Obseva eyes China re-start for fertility drug that failed trial | Reuters

ObsEva struck a pact with China’s Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a medicine that had flopped a trial.

@ Reuters | January 13, 2020

Takeda to sell stake in Chinese JV | The Pharma Letter

Japanese pharma major Takeda (TYO: 4502) is to sell its majority share in Guangdong Techpool Bio-Pharma.

Techpool is a joint venture (JV) that Takeda has held a 51.34% stake in, with a focus on the research, discovery and marketing of urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care.

@ The Pharma Letter | May 22, 2018

Shenzhen Salubris Pharmaceuticals Announces Investment and In-Licensing Agreement With MedAlliance to Bring Novel Cardiovascular Disease Therapy to China | Business Wire

Splendris International Limited, an affiliate of Shenzhen Salubris Pharmaceuticals Co Ltd. (Salubris), a multi-national leader in the development and commercialization of cardiovascular products in China and beyond, today announced a strategic investment and in-licensing agreement with Swiss cardiovascular pioneer M.A. MedAlliance S.A. (MedAlliance). Under the terms of the agreement, Salubris will make a $20 million equity investment in MedAlliance and will commit an additional $10 million in developmental milestones in exchange for exclusive rights to develop and commercialize MedAlliance’s lead investigational product Selution, a potential best-in-class sirolimus micro-reservoir drug-coated balloon (DCB), for peripheral and cardiovascular applications in the Chinese market. MedAlliance will also be eligible for royalty payments on sales.

@ Business Wire | May 21, 2018